BRS/RA Integrated Conference |
|||
| Tuesday 13th May | |||
| 07.30 | REGISTRATION | |
| 07:45-08.30 |
RENAL ASSOCIATION ANNUAL GENERAL MEETING Boisdale | |
|
08:45-10.15 |
Lomond Auditorium THE GOLDEN YEAR: ONE YEAR BEFORE RRT Chair: Brian Junor and Stuart Rodger Overview Choice Planning Pre-emptive Transplant Discussion |
ALSH DE WARDENER LECTURE Chairs: Caroline Savage & Edwina Brown Uric acid, the metabolic syndrome, and Kidney Disease O35 Primary Care Renal Disease management using a renal decision support system O36 Endothelin-A receptor antagonism offers patients with CKD cardiovascular and renal protection O37 HD facility failure to deliver optimal diabetic care to diabetic HD patients is associated with increased mortality: An international picture from DOPPS III |
| 10.15-10.45 | COFFEE & EXHIBITION POSTERS | ||||
|
10.45- 12.00 |
Lomond Auditorium
NON DIALYTIC THERAPIES O38 Symptoms in the month before death of patients with Stage 5 CKD managed conservatively, without dialysis O39 Improving the care of patients dying in the renal setting: A focus group analysis prior to implementation of the Liverpool Care Pathway O40 The Liverpool Care Pathway (LCP) for the patient dying with advanced CKD: Development of evidence-based guidelines by an expert consensus group |
Alsh
CARDIORENAL DISEASE O41 The natural history of vascular calcification in CKD – a bone to pick? Cardiovascular disease in CKD: should we give up or fight on? An optimist’s view O42 Renal function is an independent determinant of arterial stiffness and predictive of outcome in patients with coronary artery disease O43 The relationship between vascular function and survival in advanced CKD: A magnetic resonance imaging study |
Boisdale
TRANSPLANTATION O44 Is there equity of access to the Renal Transplant Waiting List in the United Kingdom? O45 Renal allograft rejection after campath induction and tacrolimus monotherapy without steroids or mycophenolate mofetil O46 Pre-emptive coronary artery angiography and revascularisation in renal transplant recipients Risk factors and the transplant assessment: old challenges, new rules? |
Carron
CKD AND PROGRESSION OF RENAL DISEASE (Renal Science) Galectin 3 and the Regulation of Renal Fibrosis O47 The Fisher-to-Lewis Model of chronic allograft nephropathy shows increased expression of transglutaminase Type 2, a protein cross-linking enzyme O48 Targeting Kirsten-Ras with antisense oligonucleotides is antifibrotic in a rat model of unilateral ureteric obstruction O49 Tubular Epithelial Mesenchymal Transformation (EMT) and The role of Albumin |
Dochart
CLINICAL TRIALS UPDATE Proposal for a UK-based randomized controlled trial of beta-blockers in advanced chronic kidney disease and dialysis patients |
| 12.00-13.30 | LUNCH & EXHIBITION & CORPORATE SESSIONS | |||
| 12.15 – 13.15
LUNCHTIME |
Alsh ROCHE
PUTTING TIME BACK INTO THE PATIENT-NURSE DIALOGUE
|
Boisdale SYNER-MED ANAEMIA IN CKD- THE FUTURE OF IV IRON TREATMENT
|
Carron WYETH IMMUNOSUPPRESSION AND MALIGNANCY- the latest update 12.15 Introduction Professor Alan Jardine, University of Glasgow 12.25 The impact of mTOR-inhibitors on the development of malignancy 12.50 Immunosuppression and skin cancer-how research can inform clinical choice 13.15 Close |
Dochart
ANNUAL RENAL SAS FORUM SAS CAREER PROGRESSION AND PMETB ARTICLE 14 APPLICATION |
|
13.30- 14.45 |
Lomond Auditorium Transplantation: Moral Maze HIGH RISK ISSUES: INTERACTIVE SESSION Invited Members of the Panel: |
Alsh THE OSMAN LECTURE Chair: Peter Mathieson, President of the Renal Association From cage to bedside: new approaches to the treatment of CKD patients O50 A20, a negative regulator of NF-KB, suppresses endothelial activation in response to Hypoxia/Re-Oxygenation and protects kidneys from Ischaemia/Reperfusion Injury O51 BMP-7 opposes TGF beta signalling via altered DNA binding and ID expression O52 Treatment of Lupus Nephritis without maintenance steroids-12 month follow up |
| 14.45-15.45 | COFFEE & EXHIBITION MODERATED POSTER SESSION | ||||
|
15.45-17.15 |
Lomond Auditorium
PERITONEAL DIALYSIS O53 Dialysate cytokines predict progression of peritoneal fibrosis in patients on PD O54 The effects of Icodextrin on Peritoneal Protein Clearance O55 Comparison of long term survivors on PD and HD O56 Plasma Volume is normal in PD patients despite an increased extracellular (ECF) to total body water (TBW) ratio |
Alsh CV evaluation of potential transplant patients Renal Vascular Disease Invited Speaker: John Main, Consultant Nephrologist, South Tees NHS Trust Radiological imaging & intervention for native fistulae |
Boisdale RUNNING THE SERVICE Chair: Jane Macdonald O57 Self-Care as a means to increasing capacity and patient choice in a HD Service O58 Access to Cadaveric Renal Transplantation – is it equitable across the UK? O59 CKD and Diabetes Mellitus in an ethnically diverse and socially deprived area – is it as bad as we think? O60 A Workforce Survey of Renal Social Workers within the United Kingdom O61 The use of assessment centres for recruitment of renal nurses |
Carron TUBULAR EPITHELIAL CELL BIOLOGY (Renal Science) Chair: Jeremy Hughes and Adrian Woolf The Regulation of EMT Invited Speaker: Roger Mason, Professor, Imperial College London Epithelial Cell Transporters Tubular morphogenesis Electrical modulation of cell behaviour
|
Dochart Palliative care Chair: Edwina Brown & Celia Eggeling Barriers to improving end of life care Learning Disabilities, Advocacy and Renal Palliative Care Communicating with patients and their families at the end of life
Achieving good symptom control for the renal patient at the end of life
|
| 17.25-18.25 |
Lomond Auditorium PATIENT PERSPECTIVE Chair: Richard Fluck Working both sides of the street – a patient’s perspective Dr. Stephen D’Souza, Consultant Radiologist, Royal Preston Hospital | ||||
| 19.45 | BRS/RA RECEPTION AND GALA DINNER – HILTON HOTEL | ||||